
GLAUCOMA
3 million people
in the U.S. have glaucoma

IMPACT OF GLAUCOMA
Glaucoma is an optic neuropathy, specifically a neurodegenerative disease, characterized by the loss of retinal ganglion cells and
their axons
Glaucoma is the second leading cause of blindness in individuals age ≥60
-
Previous studies found that GDNF reverses degeneration of the retinal nerve fiber layer. NRO-1 has an inhibitory effect of retinal ganglion cell death in an in vitro model
-
NRO-1 provided a neuroprotective effect for RGCs in a rat model of hypoxic retina
-
Pharmacokinetic studies have found that NRO-1 can reach the back of the eye in efficacious concentrations when delivered topically twice a day
We believe NRO-1 has the ability to reverse retinal degeneration in glaucoma patients for the following reasons:
Retinal mixed culture contains RGCs and glias

Neurite elongation induced by NRO-1

J Ocul Pharmacol Ther 2017; 33:556-566
NRO-1 Enhanced Neurite Elongation of Retinal Ganglion Cells